| 全球抗肿瘤药物研发报告(2016) |
| |
| 引用本文： | 毛艳艳,高柳滨.全球抗肿瘤药物研发报告(2016)[J].科技导报(北京),2016,34(11):21-24. |
| |
| 作者姓名： | 毛艳艳 高柳滨 |
| |
| 作者单位： | 中国科学院上海药物研究所, 上海 201203 |
| |
| 摘 要： | 癌症治疗是世界难题。抗肿瘤药物作为癌症治疗的重要方法之一,近年来呈现快速发展趋势,每年都有各类机构针对不同适应症、不同靶点进行大量的抗肿瘤药物开发。通过调研文献和数据库,综述了近10年来全球抗肿瘤药物的数量、研发阶段、适应证、作用机制、研发机构和销售等情况。
|
| 关 键 词： | 肿瘤 药物研发 单克隆抗体 蛋白激酶 |
| 收稿时间： | 2016-05-17 |
Report on global development of antitumor drugs (2016) |
| |
| MAO Yanyan,GAO Liubin.Report on global development of antitumor drugs (2016)[J].Science & Technology Review,2016,34(11):21-24. |
| |
| Authors: | MAO Yanyan GAO Liubin |
| |
| Institution: | Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China |
| |
| Abstract: | The treatment of cancer patients is a world-wide problem. Antitumor drugs, as one of the most important treatments for cancer patients, see a rapid growth in recent years with various institutions working in different indications and targets each year. Based on literature research and database retrieval, the global antitumor drug number, the development stages, the indications and the mechanisms, as well as research institutions and sales, are reviewed in this paper, focusing on the general trend and direction of the antitumor drug development. |
| |
| Keywords: | tumor drug research and development monoclonal antibodies protein kinase |
|
| 点击此处可从《科技导报(北京)》浏览原始摘要信息 |
| 点击此处可从《科技导报(北京)》下载免费的PDF全文 |
|
